DOCSLIB.ORG

Evidence-Based Guidelines for the Pharmacological Treatment of Schizophrenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evidence-Based Guidelines for the Pharmacological Treatment of Schizophrenia JOP0010.1177/0269881119889296Journal of PsychopharmacologyBarnes et al. 889296review-article2019 BAP Guidelines Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Journal of Psychopharmacology 1 –76 Association for Psychopharmacology © The Author(s) 2019 Article reuse guidelines: sagepub.com/journals-permissions DOI:https://doi.org/10.1177/0269881119889296 10.1177/0269881119889296 journals.sagepub.com/home/jop Thomas RE Barnes1 , Richard Drake2, Carol Paton3 , Stephen J Cooper4, Bill Deakin5, I Nicol Ferrier6, Catherine J Gregory7, Peter M Haddad8, Oliver D Howes9, Ian Jones10, Eileen M Joyce11, Shôn Lewis12, Anne Lingford-Hughes13, James H MacCabe14, David Cunningham Owens15, Maxine X Patel16, Julia MA Sinclair17, James M Stone18 , Peter S Talbot19, Rachel Upthegrove20, Angelika Wieck21 and Alison R Yung22 Abstract These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting was held in 2017, involving experts in schizophrenia and its treatment. They were asked to review key areas and consider the strength of the evidence on the risk-benefit balance of pharmacological interventions and the clinical implications, with an emphasis on meta-analyses, systematic reviews and randomised controlled trials where available, plus updates on current clinical practice. The guidelines cover the pharmacological management and treatment of schizophrenia across the various stages of the illness, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment. It is hoped that the practice recommendations presented will support clinical decision making for practitioners, serve as a source of information for patients and carers, and inform quality improvement. Keywords Guideline, schizophrenia, psychopharmacology 14 Professor of Epidemiology and Therapeutics, Department of Psychosis 1Emeritus Professor of Clinical Psychiatry, Division of Psychiatry, Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s Imperial College London, and Joint-head of the Prescribing College London, and Honorary Consultant Psychiatrist, National Observatory for Mental Health, Centre for Quality Improvement, Royal Psychosis Service, South London and Maudsley NHS Foundation Trust, College of Psychiatrists, London, UK Beckenham, UK 2 Clinical Lead for Mental Health in Working Age Adults, Health 15Professor of Clinical Psychiatry, University of Edinburgh. Honorary Innovation Manchester, University of Manchester and Greater Consultant Psychiatrist, Royal Edinburgh Hospital, Edinburgh, UK Manchester Mental Health NHS Foundation Trust, Manchester, UK 16 Honorary Clinical Senior Lecturer, King’s College London, Institute of 3 Joint-head of the Prescribing Observatory for Mental Health, Centre Psychiatry, Psychology and Neuroscience and Consultant Psychiatrist, for Quality Improvement, Royal College of Psychiatrists, London, UK Oxleas NHS Foundation Trust, London, UK 4 Emeritus Professor of Psychiatry, School of Medicine, Queen’s 17 Professor of Addiction Psychiatry, Faculty of Medicine, University of University Belfast, Belfast, UK Southampton, Southampton, UK 5 Professor of Psychiatry, Neuroscience & Psychiatry Unit, University of 18 Clinical Senior Lecturer and Honorary Consultant Psychiatrist, King’s Manchester and Greater Manchester Mental Health NHS Foundation College London, Institute of Psychiatry, Psychology and Neuroscience Trust, Manchester, UK and South London and Maudsley NHS Trust, London, UK 6Emeritus Professor of Psychiatry, Institute of Neuroscience, Newcastle 19Senior Lecturer and Honorary Consultant Psychiatrist, University of University, Newcastle upon Tyne, UK Manchester and Greater Manchester Mental Health NHS Foundation 7 Honorary Clinical Research Fellow, University of Manchester and Trust, Manchester, UK Higher Trainee in Child and Adolescent Psychiatry, Manchester 20 Professor of Psychiatry and Youth Mental Health, University University NHS Foundation Trust, Manchester, UK of Birmingham and Consultant Psychiatrist, Birmingham Early 8 Honorary Professor of Psychiatry, Division of Psychology and Mental Intervention Service, Birmingham Women’s and Children’s NHS Health, University of Manchester, UK and Senior Consultant Psychiatrist, Foundation Trust, Birmingham, UK Department of Psychiatry, Hamad Medical Corporation, Doha, Qatar 21 Honorary Consultant in Perinatal Psychiatry, Greater Manchester 9 Professor of Molecular Psychiatry, Imperial College London and Mental Health NHS Foundation Trust, Manchester, UK Institute of Psychiatry, Psychology and Neuroscience, King’s College 22 Professor of Psychiatry, University of Manchester, School of Health London, London, UK Sciences, Manchester, UK and Centre for Youth Mental Health, 10Professor of Psychiatry and Director, National Centre of Mental University of Melbourne, Australia, and Honorary Consultant Health, Cardiff University, Cardiff, UK Psychiatrist, Greater Manchester Mental Health NHS Foundation Trust, 11Professor of Neuropsychiatry, UCL Queen Square Institute of Manchester, UK Neurology, London, UK 12Professor of Adult Psychiatry, Faculty of Biology, Medicine and Corresponding author: Health, The University of Manchester, UK, and Mental Health Thomas R E Barnes, Emeritus Professor of Clinical Psychiatry, Academic Lead, Health Innovation Manchester, Manchester, UK Division of Psychiatry, Imperial College London, Du Cane Road, 13 Professor of Addiction Biology and Honorary Consultant Psychiatrist, London, W12 0NN, UK. Imperial College London and Central North West London NHS Email: [email protected] Foundation Trust, London, UK 2 Journal of Psychopharmacology 00(0) Introduction IIb: evidence from pharmacovigilance studies III: evidence from non-representative surveys, case reports The methodology for this updated guideline was essentially the IV: evidence from expert committee reports or opinions and/ same as was followed for previous British Association for or clinical experience of respected authorities Psychopharmacology (BAP) guidelines. A meeting of experts was convened in May 2017 with a remit to produce up-to-date, evi- Strength of recommendation dence-based, consensus recommendations covering the pharmaco- logical management of schizophrenia from first episode to A: directly based on category I evidence long-term relapse prevention, targeting treatment for particular per- B: directly based on category II evidence or extrapolated sistent symptoms, and strategies for refractory illness. All the con- recommendation from category I evidence tributors invited to the meeting had extensive clinical experience of C: directly based on category III evidence or extrapolated the treatment of people with schizophrenia and each of them gave a recommendation from category I or II evidence brief presentation of the published evidence relevant to the section D: directly based on category IV evidence or extrapolated of the guideline they would write. The costs of the meeting were recommendation from category I, II or III evidence defrayed by the BAP. Subsequently, the submissions from each of the co-authors were edited and integrated into a first draft which The recommendations are graded A to D, as shown above. We dis- was then circulated for further amendment and updating in 2018. A tinguish between the category of evidence and the strength of the second draft was similarly revised and updated in 2019. associated recommendation. It is possible to have methodologi- cally sound (category I) evidence about an area of practice that is clinically irrelevant or where the effect is modest and of little prac- Strength of evidence and recommendations tical significance and therefore a lower strength of recommenda- for guidelines tion is warranted. More commonly, a statement of evidence covers only one aspect of a recommendation or covers it in a way that To rank the evidence and the strength of recommendations, the conflicts with other evidence. Therefore, to produce comprehen- authors followed the categories used in the earlier, published ver- sive recommendations it is necessary to generalise from the avail- sion of this guideline (Barnes et al., 2011), which had been taken able evidence. This may lead to weaker levels of recommendation from the methodology of the North of England Evidence-Based (B, C or D) based upon category I evidence statements. Guideline Development Project, developed by the Centre for Deriving realistic, sound recommendations for clinical practice Health Services Research, University of Newcastle upon Tyne from a disparate and inconsistent evidence base is not straightfor- and the Centre for Health Economics, University of York. ward; it is not simply the application of deductive reasoning or sim- ple extrapolation. Critical appraisal of research studies and judicious Evidence categories. The six evidence categories (see Shekelle reflection on clinical experience are necessary, as well as some et al., 1999) are as follows: insight into the cognitive biases and defaults involved in the deci- sion-making process. Where recommendations were predominantly Categories of evidence for causal relationships and derived from a consensus view, in the absence of valid, systematic treatment evidence, they are graded as S (standard of good practice). Ia: evidence from meta-analysis of randomised controlled
Load more

Recommended publications
  • Systematic Review of Academic Bullying in Medical Settings: Dynamics and Consequences
    Open access Original research BMJ Open: first published as 10.1136/bmjopen-2020-043256 on 12 July 2021. Downloaded from Systematic review of academic bullying in medical settings: dynamics and consequences Tauben Averbuch ,1 Yousif Eliya,2 Harriette Gillian Christine Van Spall1,2,3 To cite: Averbuch T, Eliya Y, ABSTRACT Strengths and limitations of this study Van Spall HGC. Systematic Purpose To characterise the dynamics and consequences review of academic bullying of bullying in academic medical settings, report factors in medical settings: dynamics ► This systematic review is comprehensive, including that promote academic bullying and describe potential and consequences. BMJ Open 68 studies with 82 349 consultants and trainees, 2021;11:e043256. doi:10.1136/ interventions. across several countries and including all levels of bmjopen-2020-043256 Design Systematic review. training. We searched EMBASE and PsycINFO for Data sources ► We defined inclusion criteria a priori and used es- ► Prepublication history and articles published between 1 January 1999 and 7 February additional supplemental material tablished tools to assess the risk of bias of included for this paper are available 2021. studies. online. To view these files, Study selection We included studies conducted in ► The included studies varied in their definitions of please visit the journal online academic medical settings in which victims were bullying, sampling bias was noted among the sur- (http:// dx. doi. org/ 10. 1136/ consultants or trainees. Studies had to describe bullying veys and intervention studies were suboptimally bmjopen- 2020- 043256). behaviours; the perpetrators or victims; barriers or designed. facilitators; impact or interventions. Data were assessed Received 29 July 2020 independently by two reviewers.
    [Show full text]
  • Présentation HJ
    Conflits d’intérêts Astra-Zeneca, Janssen, Abacus international, Laboratoire ETAP, Institut Pasteur. Dr Hervé JAVELOT Pharmacien PH Etablissement Public de Santé Alsace Nord Service Pharmacie 141 avenue de Strasbourg 67 170 BRUMATH Tél. : 03 88 64 61 70 Fax : 03 88 64 61 58 Mail : [email protected] Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Hervé JAVELOT Etablissement Public de Santé Alsace Nord Perspectives dans la psychopharmacologie de l’anxiété et de la dépression Traitements des troubles anxio-dépressifs. Les perspectives. ◦ L’axe GABAergique…éternellement prometteur ? ◦ L’incontournable théorie « monoaminergique »… ◦ Des théories alternatives à suivre … Traitements des troubles anxio-dépressifs. Contexte : ◦ XXI ème siècle : Le « siècle de la dépression » s’installe ? (Hardeveld et al., 2010) L’« ère de l’angoisse » s’affirme ? (Auden, 1947) ◦ Prévalence au cours de la vie : 16 à 17% pour la dépression, 17 à 18% pour les troubles anxieux Co-morbidité des 2 troubles dans 20 à 40% des cas (Antony, 2011 ; Depping et al., 2010 ; Hardeveld et al., 2010 ; Huppert, 2009) Auden WH (1947). The Age of Anxiety: A Baroque Eclogue. Random House: New York. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184-91. Antony MM. Recent advances in the treatment of anxiety disorders. Canadian Psychology 2011;52(1), 10-19. Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120. Huppert JD. Anxiety disorders and depression comorbidity.
    [Show full text]
  • A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling
    biomolecules Review Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling Christopher L. Cioffi Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA; christopher.cioffi@acphs.edu; Tel.: +1-518-694-7224 Abstract: Among the myriad of cellular and molecular processes identified as contributing to patho- logical pain, disinhibition of spinal cord nociceptive signaling to higher cortical centers plays a critical role. Importantly, evidence suggests that impaired glycinergic neurotransmission develops in the dorsal horn of the spinal cord in inflammatory and neuropathic pain models and is a key maladaptive mechanism causing mechanical hyperalgesia and allodynia. Thus, it has been hypothesized that pharmacological agents capable of augmenting glycinergic tone within the dorsal horn may be able to blunt or block aberrant nociceptor signaling to the brain and serve as a novel class of analgesics for various pathological pain states. Indeed, drugs that enhance dysfunctional glycinergic transmission, and in particular inhibitors of the glycine transporters (GlyT1 and GlyT2), are generating widespread + − interest as a potential class of novel analgesics. The GlyTs are Na /Cl -dependent transporters of the solute carrier 6 (SLC6) family and it has been proposed that the inhibition of them presents a Citation: Cioffi, C.L. Inhibition of possible mechanism
    [Show full text]
  • The Legal 'Face' of Mobbing
    SEE - A Fortnight in Review February 13th legal | by Milica Janković Milica Janković specialises in targeting the victim’s congenital or ac- Labour Law at Belgrade's JPM - quired traits which are irrelevant to the Janković, Popović & Mitić Law Firm (www.jpm.rs). She may be reached performance of a specific job, since that The Typology at [email protected]. would constitute discrimination. Serbian jurisprudence, because of the insufficient level of professional expertise and difficulties in obtaining proof, is still With some variations, the following typology of behaviours has been adopted by several steps behind in this field, both as a number of academic researchers. The typology uses five different categories: The Legal ‘Face’ 4 Discrediting the victim’s profession- compared to western European methods al and work capacity: Giving the victim in determining the existence of stress and > Threat to professional status – including belittling opinions, public pro- tasks that are far below or above his/her mobbing in the workplace and in terms fessional humiliation, accusations regarding lack of effort, intimidating use of of Mobbing capabilities, or not permitting the victim of the damages awarded to the claimant. discipline or competence procedures to do anything, criticising his/her slight- The Anti-Mobbing Law is quite “fresh” > Threat to personal standing – including undermining personal integrity, est mistakes and omissions, ridiculing (enacted in 2010), so the court practice destructive innuendo and sarcasm, making inappropriate
    [Show full text]
  • Role of Prefrontal Cortex and Cholinergic Modulation in Attentional
    Role of prefrontal cortex and cholinergic modulation in attentional performance in rats Beth Mary Fisher Department of Psychology Downing College University of Cambridge September 2017 This dissertation is submitted for the degree of Doctor of Philosophy Declaration This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as declared in the Preface and specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. It does not exceed the prescribed word limit of the degree committee for the faculty of biology of 60,000 words. i2 Acknowledgements Firstly, I would like to thank my supervisor Tim Bussey and advisor Trevor Robbins for their invaluable support, guidance and encouragement throughout my PhD. Their insightful scientific discussions, passion for the field and praise of me, have shaped me to become a scientist I am proud of, and given me an unknown confidence. Not only are they experts in the field, but they are down to earth, kind and fun.
    [Show full text]
  • Stapleton2018.Pdf (2.527Mb)
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Institutions In/Cognito: The Political Constitution of Agency Sarah Jane Stapleton PhD in Sociology The University of Edinburgh 2018 Declaration of Authorship I, Esje Stapleton, declare that this thesis is composed by me and that all the work herein is my own, unless explicitly attributed to others. This work has not been submitted for any other degree or professional qualification. Sarah Jane Stapleton, 29th March, 2018 I Abstract Operating at the boundaries of philosophy of mind, cognitive science, politics and social theory, this thesis aims to develop an interdisciplinary model of the relationship between agency and structure. This thesis explores the question of why the agency/structure argument in the social sciences has not yet been resolved and argues for an interdisciplinary model of agency to be utilised by social theory.
    [Show full text]
  • Towards a Framework for Understanding Discursive Regime Destabilisation: a Case Study of a Social Movement Organisation “Economy for the Common Good”
    sustainability Article Towards a Framework for Understanding Discursive Regime Destabilisation: A Case Study of a Social Movement Organisation “Economy for the Common Good” Olga Koretskaya 1,* and Christian Scholl 2 1 Copernicus Institute of Sustainable Development, Utrecht University, 3584 CB Utrecht, The Netherlands 2 International Centre for Integrated Assessment and Sustainable Development, Maastricht University, 6200 MD Maastricht, The Netherlands * Correspondence: [email protected] Received: 9 May 2019; Accepted: 8 August 2019; Published: 13 August 2019 Abstract: Despite increasing scepticism about the conventional growth model, the topic of destabilisation of socio-economic regimes has not yet captured scholarly interest. This paper addresses this gap and serves a twofold purpose. First, it develops an analytical framework for studying discursive regime destabilisation based on previous research by Turnheim and colleagues. The framework is novel as it allows for: (1) structured analysis of framing interactions between niche and regime actors; (2) visualised mapping of discursive actors; and (3) identification of phases of discursive destabilisation. Second, the paper contributes to the literature on an ongoing practice of socio-economic transformations by applying the framework to a case study of a social movement organisation, “Economy for the Common Good” (ECG), that seeks to advance socio-economic transition. The suggested framework was useful for analysing the ECG. First, it demonstrated that niche actors employed mostly motivational and prognostic frames supporting the alternative economic approach, while the regime diffused mostly diagnostic frames focusing on the perceived negative aspects of the niche. Second, by applying the framework, we identified three relevant destabilisation phases in this socio-economic transformation process: Blindness and Denial, Incremental Responses to Problems and Increasing Doubts and Diversification.
    [Show full text]
  • Family Violence Screening and Intervention
    A Better Start E Tipu e Rea Brief Evidence Reviews for the Well Child Tamariki Ora Programme Report submitted to MoH on 11 December 2019 Whakapūpūtia mai ō mānuka, kia kore ai e whati Cluster the branches of the manuka, so they will not break Foreword The Ministry of Health is responsible for the development of policy advice on children’s health and the future direction of the Well Child Tamariki Ora (WCTO) programme. The WCTO programme is the universal health service in New Zealand, which is responsible for protecting and improving the health and wellbeing of children from birth to 5 years of age. This is achieved through health and development screening and surveillance, whānau care and support, and health education. The current programme is based on the evidence available at the time of the last programme update in 2007. Therefore, the Ministry of Health is reviewing the current WCTO Framework and associated Schedule (developed in 2002) to ensure that WCTO services meet the current needs of children and their whānau, and address the issues they face. The present review was initiated in 2019 and is the second review of the programme, as the first was carried out in 2006. In preparation for this review, the Ministry of Health has commissioned an evaluation of the recent literature on some of the new and emerging issues for preschool children, as well as possible ways to address them. The purpose of this review includes ensuring that the programme is underpinned by the latest research and evidence. This is particularly pertinent to the current Schedule of Universal Contacts delivered, and one of the work-streams of the review is to consider the timing, content, and intensity of the Schedule, and associated additional contacts.
    [Show full text]
  • Hayward Et Al, 2017
    European Neuropsychopharmacology (]]]]) ], ]]]–]]] www.elsevier.com/locate/euroneuro Partial agonism at the α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats Andrew Haywardn, Lisa Adamson, Joanna C. Neilln Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester M13 9PT, UK Received 7 July 2016; received in revised form 9 January 2017; accepted 18 January 2017 KEYWORDS Abstract 5 choice-continuous Inattention is a disabling symptom in conditions such as schizophrenia and attention deficit/ performance task; hyperactivity disorder. Nicotine can improve attention and vigilance, but is unsuitable for clinical use 5C-CPT; due to abuse liability. Genetic knockout of the α7 nicotinic acetylcholine receptor (nAChR) induces α 7 nAChR; attention deficits therefore selective agonism may improve attention, without the abuse liability Animal Model; associated with nicotine. The α7 nAChR partial agonist encenicline (formerly EVP-6124) enhances Behavioural separa- memory in rodents and humans. Here we investigate, for the first time, efficacy of encenicline to tion; Low attentive improve attention and vigilance in animals behaviourally grouped for low attentive traits in the 5 choice-continuous performance task (5C-CPT). Female Lister Hooded rats were trained to perform the5C-CPTwithavariablestimulusduration(SD).Animalswerethengroupedbasedonperformance intoupperandlowerquartilesofd0 (vigilance) and accuracy (selective attention), producing high- attentive (HA) and low-attentive (LA) groups. LA animals showed an increase in selective attention and vigilance at 0.3 mg/kg encenicline, a reduction in impulsive action (probability of false alarms) and increase in vigilance following 1 mg/kg at 0.75 s SD. At 1 mg/kg, HA animals had reduced selective attention at 0.75 s SD and reduced vigilance at 0.75 and 1.25 s SD.
    [Show full text]
  • Targeting Glycine Reuptake in Alcohol Seeking and Relapse
    JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. TITLE PAGE Targeting Glycine Reuptake in Alcohol Seeking and Relapse Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov, Rainer Spanagel Downloaded from The primary laboratory of origin: Institute of Psychopharmacology, Central Institute of jpet.aspetjournals.org Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; at ASPET Journals on September 30, 2021 VV, MR, TTT, RS: Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; DA: Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland; BB, AB: Department of Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; AB: Department of Psychopharmacology, Pavlov Medical University, St Petersburg, Russia JPET #244822 JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. RUNNING TITLE GlyT1 in Alcohol Seeking and Relapse Corresponding author with complete address: Valentina Vengeliene, Institute of Psychopharmacology, Central Institute of Mental Health (CIMH), J5, 68159 Mannheim, Germany Email: [email protected], phone: +49-621-17036261; fax: +49-621- Downloaded from 17036255 jpet.aspetjournals.org The number of text pages: 33 Number of tables: 0 Number of figures: 6 Number of references: 44 at ASPET Journals on September 30, 2021 Number of words in the Abstract: 153 Number of words in the Introduction: 729 Number of words in the Discussion: 999 A recommended section assignment to guide the listing in the table of content: Drug Discovery and Translational Medicine 2 JPET #244822 JPET Fast Forward.
    [Show full text]
  • Treatment of Schizophrenia Course Director: Philip Janicak, M.D
    S6735- Treatment of Schizophrenia Course Director: Philip Janicak, M.D. #APAAM2016 Saturday, May 14, 2016 Marriott Marquis - Marquis Ballroom D psychiatry.org/ annualmeetingS4637 ANNUAL MEETING May 14-18, 2016 • Atlanta Reference • Janicak PG, Marder SR, Tandon R, Goldman M (Eds.). Schizophrenia: Recent Advances in Diagnosis and Treatment. New York, NY: Springer; 2014. Schizophrenia: Recent Diagnostic Advances, Neurobiology, and the Neuropharmacology of Antipsychotic Drug Therapy Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine Gainesville, Florida Annual Meeting of the American Psychiatric Association New York, New York May 3–7, 2014 Disclosure Information MEMBER, WPA PHARMACOPSYCHIATRY SECTION MEMBER, DSM-5 WORKGROUP ON PSYCHOTIC DISORDERS A CLINICIAN AND CLINICAL RESEARCHER Pharmacological Treatment of Any Disease • Know the Disease that you are treating • Nature; Treatment targets; Treatment goals; • Know the Treatments at your disposal • What they do; How they compare; Costs; • Principles of Treatment • Measurement-based; Targeted; Individualized Program Outline • Nature and Definition of psychosis? • Clinical description • What is wrong in psychotic illness • Dimensions of Psychopathology • Neurobiological Abnormalities • Mechanisms underlying antipsychotic effects? • What contributes to Efficacy • Basis of Side-effect differences 5 Challenges in DSM-IV Construct of Psychotic Disorders ♦ Indistinct Boundaries ♦ With Other Disorders (eg., with OCD) ♦ Within Group of Psychotic Disorders (eg. between
    [Show full text]
  • (Tert- Butoxycarbonyl)Amino](3 361442- 3
    Alternative Name CAS 1. Product Name Use Number 320345- 2. Aclidinium bromide API 99-1 (2S)-[(tert- Butoxycarbonyl)amino](3 361442- 3. Saxagliptin int -hydroxyadamant-1- 00-4 yl)ethanoic acid 1,3- 1,3- 5001-18- 4. Dihydroxyadamantane Adamantanediol 3 1,3-Dimethyladamantane 702-79-4 memantine intermediate 5. 1-Acetylamido-3,5- 19982- 6. Memantine int dimethyladamantane 07-1 1- 7. 880-52-4 Acetylaminoadamantane 1- 4942-47- 8. 1-Adamantaneacetic acid Adamantylacetic 6 acid [2-(1- 6240-11- 9. 1-Adamantaneethanol Adamantylethano 5 l)] 1- 10. 1-Adamantanemethanol Adamantylmetha 770-71-8 nol 1- 1660-04- 1-Adamantyl methyl rimantadine intermediate; 11. Acetyladamantan 4 ketone e 1-Chloro-3,5- 707-36-8 memantine intermediate; 12. dimethyladamantane 1-Hydroxy-3,5- memantine intermediate; 13. 707-37-9 dimethyladamantane 2- 14. 2-Adamantanol Hydroxyadamant 700-57-2 ane 15. 2-Adamantanone 700-58-3 2-Aminoadamantane 10523- 16. hydrochloride 68-9 3-Amino-1-hydroxy- 3-Amino-1- 702-82-9 vildagliptin intermediate; 17. adamantane adamantanol 3- 38584- 18. (Hydroxymethyl)adamant 37-1 -1-ol 19. 3-aminomethyl- 865887- mequitazine intermediate; 20. quinuclidine 14-5 dihydrochloride zacopride intermediate; 6530-09- mezacopride intermediate; 3-Aminoquinuclidine 21. 2 pancopride intermediate; dihydrochloride azasetron intermediate; 3-Carbethoxy-dehydro- quifenadine intermediate; 50790- 22. quinuclidine sequifenadine intermediate; 85-7 hydrochloride quifenadine intermediate; 3- 6238-33- 23. sequifenadine intermediate; Carbethoxyquinuclidine 1 3-hydroxymethyl 79221- mequitazine intermediate; 24. quinuclidine 75-3 hydrochloride 3-Quinuclidine 6238-34- 25. carboxylic acid 2 hydrochloride 1619-34- penehyclidine intermediate; 26. 3-Quinuclidinol 7 clidinium intermediate; cevimeline intermediate; 3-Quinuclidinone 1193-65- 27.
    [Show full text]